

For Immediate Release

October 18, 2017

## **ENDOCAN SOLUTIONS ANNOUNCES MANAGEMENT CHANGES**

Vancouver, B.C., October 18, 2017 – Endocan Solutions Inc. (CSE: WWM-Delisted) (the "Company" or "Endocan") is pleased to announce that Mr. Chris L. MacPherson is joining the Company as Chief Financial Officer. Chris spent 25 years at CIBC Wood Gundy as Vice President & Portfolio Manager, and has extensive experience in the capital markets, as well as a C-Suite executive in the private and public venture capital space.

Chris will be responsible for finance and marketing activities, funding and acquisition opportunities as well as assist in strategic and tactical matters. Chris has sat on several boards, including BC Hydro, and has been active on the political stage. He has also been involved in a number of charities, including Children's Miracle and Nepal House Society. Ms. Annie Storey has stepped down as CFO but remains as a Company director.

About Endocan Solutions Inc.

Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the CSE on December 6, 2016, subsequently put under new management, and recently underwent a name change and share consolidation. The immediate objective is to bring the Company's filings up to date under National Instrument 51-102, which includes audited annual financial statements, quarterlies, MD&As and Officer Certificates for the years ended October 31, 2015, 2016 and 2017. Following completion of these filings, the Company intends to seek and secure a suitable business acquisition and regualify to meet the listing requirements of the Exchange as a Life Sciences Issuer.

## ON BEHALF OF ENDOCAN SOLUTIONS INC.

(signed) "Robert van Santen"
Chief Executive Officer

## For further information, please contact:

Greg Patchell

Telephone: +1.250.860.8634

Cautionary statements

This press release contains forward-looking information based on current expectations. Statements about the Company's expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Endocan Solutions assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of

the Canadian We seek safe	Securities harbor.	Exchange)	accepts	responsibility	for the	adequacy	or accuracy	of this re	elease